FR2688405B1 - Procede d'une preparation d'une solution medicinale stable pour voie orale a liberation controlee, a base d'un beta-bloquant, et composition pharmaceutique a base d'un beta-bloquant. - Google Patents

Procede d'une preparation d'une solution medicinale stable pour voie orale a liberation controlee, a base d'un beta-bloquant, et composition pharmaceutique a base d'un beta-bloquant.

Info

Publication number
FR2688405B1
FR2688405B1 FR9205275A FR9205275A FR2688405B1 FR 2688405 B1 FR2688405 B1 FR 2688405B1 FR 9205275 A FR9205275 A FR 9205275A FR 9205275 A FR9205275 A FR 9205275A FR 2688405 B1 FR2688405 B1 FR 2688405B1
Authority
FR
France
Prior art keywords
blocker
beta
preparation
pharmaceutical composition
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9205275A
Other languages
English (en)
Other versions
FR2688405A1 (fr
Inventor
Istvan Racz
Sylvia Marton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synepos AG
Original Assignee
Synepos AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synepos AG filed Critical Synepos AG
Publication of FR2688405A1 publication Critical patent/FR2688405A1/fr
Application granted granted Critical
Publication of FR2688405B1 publication Critical patent/FR2688405B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
FR9205275A 1992-03-13 1992-04-29 Procede d'une preparation d'une solution medicinale stable pour voie orale a liberation controlee, a base d'un beta-bloquant, et composition pharmaceutique a base d'un beta-bloquant. Expired - Fee Related FR2688405B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9200866A HU209251B (en) 1992-03-13 1992-03-13 Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons
US08/135,992 US5484776A (en) 1992-03-13 1993-10-14 Process for the production of stable liquid form of beta-blocker-containing medicaments with controlled release of the active constituent for oral administration

Publications (2)

Publication Number Publication Date
FR2688405A1 FR2688405A1 (fr) 1993-09-17
FR2688405B1 true FR2688405B1 (fr) 1995-03-03

Family

ID=26318071

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9205275A Expired - Fee Related FR2688405B1 (fr) 1992-03-13 1992-04-29 Procede d'une preparation d'une solution medicinale stable pour voie orale a liberation controlee, a base d'un beta-bloquant, et composition pharmaceutique a base d'un beta-bloquant.

Country Status (7)

Country Link
US (1) US5484776A (fr)
DE (1) DE4212640A1 (fr)
FR (1) FR2688405B1 (fr)
GB (1) GB2264866A (fr)
HU (1) HU209251B (fr)
IT (1) IT1254953B (fr)
SE (1) SE9201208L (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4331539A1 (de) * 1993-09-17 1995-03-23 Basf Ag Dextranester, Verfahren zu ihrer Herstellung und ihre Verwendung zur Umhüllung oder Einbettung von Arzneimitteln
US5399358A (en) * 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
ES2246961T3 (es) * 1994-04-25 2006-03-01 Penwest Pharmaceuticals Co. Excipiente de liberacion sostenida.
US5399362A (en) * 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
AU2068797A (en) * 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
JPH10139670A (ja) * 1996-11-11 1998-05-26 Terukuni Yakida インターロイキン１２誘導物質及び医薬組成物
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
EP1113785B1 (fr) 1998-07-24 2005-04-13 Seo Hong Yoo Solutions claires aqueuses avec des acides biliaires
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
KR100848344B1 (ko) * 2000-02-04 2008-07-25 유서홍 담즙산 함유 청정 수용액 제형의 제조
EP1499295A4 (fr) * 2002-04-05 2006-04-05 Penwest Pharmaceuticals Co Formulations de metoprolol a liberation prolongee
US7145125B2 (en) * 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
BRPI0514725A (pt) * 2004-08-30 2008-06-24 Seo Hong Yoo efeito neuroprotetor de udca solubilizado no modelo isquêmico focal
EP1809330B1 (fr) * 2004-10-15 2011-04-27 Seo Hong Yoo Methodes et compositions pour reduire la toxicite du cisplatine, carboplatine, et de l'oxaliplatine
EP2255812A1 (fr) * 2004-11-01 2010-12-01 Seo Hong Yoo Méthodes et composés pour la réduction de la neurodegénération dans la sclérose latérale amyotrophique.
DE102006020604A1 (de) * 2006-05-02 2007-11-08 Bayer Healthcare Ag Flüssige Arzneimittelformulierung
EP2246044A1 (fr) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Solutions pédiatriques de bêta-bloquants
US9724297B2 (en) 2014-04-01 2017-08-08 Arbor Pharmaceuticals, Inc. Sotalol compositions and uses of the same
GB2593902B (en) 2020-04-07 2022-04-13 Actimed Therapeutics Ltd Salt of a pharmaceutical compound

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB993584A (fr) * 1962-01-24
US4136173A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
SE441525B (sv) * 1978-05-19 1985-10-14 Ici Ltd P-hydroxifenylettiksyra
US4394390A (en) * 1979-08-03 1983-07-19 University Of Kentucky Research Foundation Nasal dosage forms of propranol
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4248858A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4428883A (en) * 1981-03-06 1984-01-31 The University Of Kentucky Research Foundation Novel method of administering β-blockers and novel dosage forms containing same
JPS59130866A (ja) * 1983-01-17 1984-07-27 Zeria Shinyaku Kogyo Kk ピンドロ−ル製剤の製造法
US4689235A (en) * 1984-01-31 1987-08-25 Scm Corporation Encapsulation matrix composition and encapsulate containing same
GB8402573D0 (en) * 1984-02-01 1984-03-07 Fisons Plc Oral formulation
US4579867A (en) * 1984-04-09 1986-04-01 American Hospital Supply Corporation Stable pharmaceutical compositions of short-acting β-adrenergic receptor blocking agents
US4885293A (en) * 1984-09-24 1989-12-05 Schering Corporation Antiglaucoma agents
US4600708A (en) * 1985-07-19 1986-07-15 American Home Products Corporation Propranolol hydrochloride liquid formulations
GB8522453D0 (en) * 1985-09-11 1985-10-16 Lilly Industries Ltd Chewable capsules
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
IT1234194B (it) * 1988-05-31 1992-05-06 Magis Farmaceutici Composizioni farmaceutiche in forma di sciroppo contenenti pentitoli quali agenti di veicolazione
DE4004656C1 (fr) * 1990-02-15 1991-05-02 Melitta Haushaltsprodukte Gmbh & Co Kg, 4950 Minden, De
US5100688A (en) * 1990-02-23 1992-03-31 Cox James P Saccharide/protein gel
US5225219A (en) * 1992-01-02 1993-07-06 The United States Of America, As Represented By The Secretary Of Agriculture Amylodextrin compositions and method therefor

Also Published As

Publication number Publication date
ITMI921022A1 (it) 1993-10-30
IT1254953B (it) 1995-10-11
HU9200866D0 (en) 1992-05-28
GB2264866A (en) 1993-09-15
US5484776A (en) 1996-01-16
FR2688405A1 (fr) 1993-09-17
ITMI921022A0 (it) 1992-04-30
SE9201208L (sv) 1993-09-14
GB9208518D0 (en) 1992-06-03
HU209251B (en) 1994-04-28
SE9201208D0 (sv) 1992-04-15
HUT63580A (en) 1993-09-28
DE4212640A1 (de) 1993-09-16

Similar Documents

Publication Publication Date Title
FR2688405B1 (fr) Procede d'une preparation d'une solution medicinale stable pour voie orale a liberation controlee, a base d'un beta-bloquant, et composition pharmaceutique a base d'un beta-bloquant.
FR2680109B1 (fr) Composition pour la liberation prolongee et controlee et controlee d'une substance medicamenteuse peptidique et procede pour sa preparation.
FR2761266B1 (fr) Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
FR2761265B1 (fr) Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
MA26471A1 (fr) Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA22894A1 (fr) Procede de preparation d'un vaccin.
FR2613624B1 (fr) Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
FR2734483B1 (fr) Forme d'administration pharmaceutique comprenant de l'oxybutynine
MA22819A1 (fr) Procede de preparation d'un nouveau produit pharmaceutique.
OA09415A (fr) "Composition pharmaceutique pour administration orale à base d'un dérivé d'acide diphosphonique".
DZ2420A1 (fr) Formulations nouvelles comprenant l'amoxycilline et du clavulanate et procédé pour leur préparation.
DZ2600A1 (fr) Associations pharmaceutiques d'amlodipine et d'unestatine et procédé pour leur préparation.
FR2701708B1 (fr) Dérivés de 2-amido-4-phénylthiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament.
MC1915A1 (fr) Procédés pour la préparation de 2',3'-didésoxynucléosides et de formulations pharmaceutiques en contenant
FR2611501B1 (fr) Nouvelles compositions pharmaceutiques pour la voie buccale a base d'acetylsalielylate de lysine et leur procede d'obtention
MA22443A1 (fr) Procede de preparation d'une composition pharmaceutique .
FR2754177B1 (fr) Microspheres pharmaceutiques d'acide valproique pour administration orale
MA24183A1 (fr) Procede pour la preparation de compositions pharmaceutiques a base de diclofenac
FR2754710B1 (fr) Procede de preparation d'une forme pharmaceutique multiparticulaire a liberation controlee plurisequentielle
FR2701478B1 (fr) Dérivés de vitamine E contenant de l'azote quaternaire et procédés pour leur préparation.
FR2647346B1 (fr) Compose de progesterone stabilisee, procede pour sa preparation, et utilisation de ce compose pour l'obtention d'un medicament
DZ2619A1 (fr) Procédé pour la préparation d'acides 4-phényl-4-cyanocyclohexanoïques substitués.
FR2654341B1 (fr) Utilisation d'ifenprodil et de ses derives pour la fabrication de medicaments antipsychotiques.
FR2657872B2 (fr) Derive d'amidino-4 chromanne, procede d'obtention et compositions pharmaceutiques le contenant.
FR2668707B1 (fr) Procede de preparation d'une composition pharmaceutique.

Legal Events

Date Code Title Description
ST Notification of lapse